effect of semaglutide on chronic kidney disease Diabetes Distilled: Keeping kidneys FLOWing – improves renal outcomes Semaglutide, Chronic Kidney Disease, and

364 Mertens, P

Contribution statement JIM contributed to the design of the study, constructed the model, performed the analysis and literature search, acquisition and interpretation of the data, and wrote and revised the manuscript

Documented Benefits in Published Models Mean GH concentrations increased two- to ten-fold for six days after a single dose (Teichman et al., 2006) PubMed Ipamorelin is a pentapeptide which displays high GH-releasing potency and efficacy in vitro and in vivo (Raun et al., 1998) PubMed Collectively, studies show: Enhanced mitochondrial oxidative capacity in isolated rat myofibers ( citrate synthase activity, p 12 weeks Contraindications for in-vivo work (if ever pursued under an authorized IND) would logically include diabetes, proliferative neoplasms, or active retinopathyconditions in which GH/IGF-1 exaggeration poses theoretical risk

A modelbased approach to predict individual weight loss with semaglutide in people with overweight or obesity

Exploratory REMAIN-1 Midpoint Cohort subgroup